The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus
Abstract
INTRODUCTION: Gestational diabetes mellitus (GDM) complicates 10% of all pregnancies and is defined as hyperglycemia first noted during pregnancy. Rates of GDM are rising and untreated GDM results in complications for both mother and fetus. GDM is often managed by diet and exercise but 30-40% of women will require pharmacological intervention. Insulin has traditionally been the treatment of choice but since 2007, glyburide, a second generation sulfonylurea has become the most prescribed medication for GDM. AREAS COVERED: This review will cover the pharmacokinetics, efficacy, and safety of glyburide for the management of GDM. EXPERT OPINION: Management of GDM is challenging secondary to the stringent glycemic goals that mimic the lower glucose levels in pregnancy. Glyburide is generally effective in treating hyperglycemia. However, several studies have raised safety concerns showing higher neonatal intensive care unit (NICU) admissions, higher rates of macrosomia, large for gestational age and pre-eclampsia in the mother. For this reason, insulin should be first-line therapy for GDM. In areas of limited resources where the self-monitoring needed for accurate insulin dosing is not possible, where access to refrigeration for insulin storage is not universal, or severe needle phobia then the benefits of glyburide (controlling hyperglycemia) outweighs the harm of NICU admissions and macrosomia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concentrations of glyburide in umbilical cord plasma are approximately 50-70% of maternal levels (76,77).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [77]
In the citing paper
“Furthermore, in separate RCTs, glyburide and metformin failed to provide adequate glycemic outcomes in 23% and 25-28% of participants with GDM, respectively (76,77).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [77]
In the citing paper
“Sulfonylureas are known to cross the placenta and have been associated with increased neonatal hypoglycemia.”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [77]
Citations
Cites
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
Gestational Diabetes and the Incidence of Type 2 Diabetes
Kim, C., Newton, K. M., & Knopp, R. H. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1862 · Cited by 2,276 · cited 5×
“With these facts in mind, this paper will review the pharmacokinetics (PK), efficacy, and safety of this medication for treatment of GDM.”
BackgroundInfluentialBanting lecture 1980: of pregnancy and progeny.
Freinkel, N. (1980) · Diabetes · doi:10.2337/diab.29.12.1023 · Cited by 1,366
Banting Lecture 1980. Of pregnancy and progeny
Freinkel, N. (1980) · Diabetes · doi:10.2337/diabetes.29.12.1023 · Cited by 1,366
Increasing Prevalence of Gestational Diabetes Mellitus
Ferrara, A. (2007) · Diabetes Care · doi:10.2337/dc07-s206 · Cited by 1,171 · cited 1×
“It complicates up to 10% of all pregnancies, and rates are rising in the setting of increasing maternal age, obesity, and family history of diabetes.[1] Untreated hyperglycemia during the first trimester of pregnancy is associated with structural malformations and miscarriage.”
BackgroundMaliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 8×
“With these facts in mind, this paper will review the pharmacokinetics (PK), efficacy, and safety of this medication for treatment of GDM.”
MethodResultInfluentialClausen, T. D., Mathiesen, E. R., Hansen, T., Pedersen, O., Jensen, D. M., Lauenborg, J., & Damm, P. (2008) · Diabetes Care · doi:10.2337/dc07-1596 · Cited by 724
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010
Stark Casagrande, S., Fradkin, J. E., Saydah, S. H., Rust, K. F., & Cowie, C. C. (2013) · Diabetes Care · doi:10.2337/dc12-2258 · Cited by 719 · cited 1×
“Only about 50% of individuals with type 2 DM reach glucose goals defined as glycated hemoglobin <7% (average glucose 150 mg/dL).[49] There is an obvious alternative to glyburide and that is insulin therapy (see Table 2 for comparison).”
BackgroundWendland, E. M., Torloni, M. R., Falavigna, M., Trujillo, J., Dode, M. A., Campos, M. A., Duncan, B. B., & Schmidt, M. I. (2012) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-12-23 · Cited by 626 · cited 2×
“[1] Untreated hyperglycemia during the first trimester of pregnancy is associated with structural malformations and miscarriage.[2,3] During the second and third trimester, uncontrolled hyperglycemia leads to increased fetal size with the risk of macrosomia and associated obstetrical complications such as shoulder dys…”
Background
Research works printed but not linked: 2
- Maliepaard M, 2001, Cancer Res, 61, 3458
- Mirzamoradi M, 2015, Acta Med Iran, 53, 97
Cited by
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s014 · Cited by 265
“Concentrations of glyburide in umbilical cord plasma are approximately 70% of maternal levels (44,45).”
Background
Metadata
- Authors
- Malek, R., & Davis, S. N.
- Affiliations
- University of Maryland, Baltimore (US)
- University of Maryland Medical Center (US)
- Corresponding author
- Davis, Stephen N.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2016-05-23
- Volume
- 12
- Issue
- 6
- Pages
- 691-699
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2362195380
- Cited by
- 54
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 10 · 2019: 3 · 2018: 6 · 2017: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Metabolism & Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- glibenclamide, gestational diabetes mellitus, sulfonylureas, pharmacokinetics, drug safety, glycemic control, neonatal intensive care admission, macrosomia, preeclampsia, insulin therapy, antidiabetic drugs
- MeSH terms
- Animals, Blood Glucose, Female, Glyburide, Humans, Hypoglycemic Agents, Infant, Newborn, Insulin, Intensive Care Units, Neonatal, Pregnancy, Diabetes, Gestational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus. https://app.cochat.ai/papers/10.1080/17425255.2016.1187131
- The paper
- Malek, R., & Davis, S. N. (2016). Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1080/17425255.2016.1187131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.